When was SeQuent founded?

SeQuent was founded in 2002 and raised its 1st funding round 12 years after it was founded.

Where is SeQuent located?

SeQuent is headquartered in Bengaluru, India. It is registered at 3rd Floor, Srivalli s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India, 500033.

Which legal entities is SeQuent associated with?

SeQuent is associated with Sequent Scientific Limited and 2 others.

How many employees does SeQuent have?

As of Jul 31, 2026, the latest employee count at SeQuent is 2.

Is SeQuent an acquired company?

SeQuent got acquired by The Carlyle Group and undefined on May 08, 2020.

Is SeQuent a funded company?

SeQuent is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Apr 2014.

When was the latest funding round of SeQuent?

SeQuent's latest funding was a $***** Post IPO round on Jun 29, 2020, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. In India, the Biopharma Outsourcing sector has seen $333M in funding in 2026 to date.

What is the annual revenue of SeQuent?

Annual revenue of SeQuent is more than ₹1,000 Cr as on Mar 31, 2022

Where does SeQuent rank among its competitors?

SeQuent ranks 7th amongst 962 active competitors, of which 38 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Embio, which secured $50M in May, 2026.

Who are the top competitors of SeQuent?

SeQuent's top competitors include Laurus Labs, Symbiotec and Embio. Among them, Embio secured the most recent funding round in May, 2026.

SeQuent - 2026 Company Profile, Team, Funding, Competitors & Financials

SeQuent is an acquired company based in Bengaluru (India), founded in 2002. It operates as an APIs Manufacturer. SeQuent has raised an undisclosed amount in funding. The company has 962 active competitors, including 38 funded and 138 that have exited. Its top competitors include companies like Laurus Labs, Symbiotec and Embio.

Company Details

SeQuent is into developing and manufacturing of APIs for multiple therapeutic areas with three manufacturing facilities in Karnataka and Maharashtra. SeQuent Research Limited (SRL) is the research arm of Sequent offering contract research services specialized in Analytical and Bio Analytical Services to support the API, Pharmaceutical, Personal Care and Nutraceutical companies

Website: sequent.in
Social
Registered Address: 3rd Floor, Srivalli s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India, 500033

Key Metrics

Founded Year

2002

Location

Bengaluru, India

Stage

Acquired

Latest Funding Round

Post IPO, Jun 29, 2020, $*****

Investors

Nepean Capital & 3 more

Ranked

7^th among 962 active competitors

Annual Revenue

₹1,000+ Cr as on Mar 31, 2022

Employee Count

2 as on Jul 31, 2026

Investment & Acquisitions

Indo Phyto Chemicals

Similar Companies

Laurus Labs & 1226 more

Exit Details

Acquired by The Carlyle Group (May 08, 2020)

View SeQuent's full profile

SeQuent is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
Sequent Research Limited CIN: U24232TS2007PLC196886 , India, Amalgamated	Apr 13, 2007	0 - ₹10 Cr (As on Mar 31, 2025)	49 (As on Nov 30, 2024)
Sequent Scientific Limited CIN: U24110MH2002PLC136868 , India, Amalgamated	Aug 16, 2002	₹1,000+ Cr (As on Mar 31, 2022)	352 (As on Mar 31, 2024)
VIYASH SCIENTIFIC LIMITED CIN: L99999TS1985PLC196357 , India, Active	Jun 28, 1985	₹1,000+ Cr (As on Mar 31, 2025)	349 (As on Feb 01, 2026)

SeQuent got acquired by The Carlyle Group and on May 08, 2020.

Click here to take a look at SeQuent's acquisition in detail

SeQuent has raised funding over 3 rounds. Its first funding round was on Apr 2014. Its latest funding round was a Post IPO round on Jun 29, 2020 for $*****. 1 investor participated in its latest round. SeQuent has 4 institutional investors.

Here is the list of recent funding rounds of SeQuent:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 29, 2020	9018910	Post IPO	3865776	4028876	7324387	7300215
May 26, 2015	2623525	Post IPO	6697545	7425471	2423351	3401404
Apr 2014	5568390	Post IPO	9294829	1787396	7415416	Ascent Capital

Access funding benchmarks and valuations. Sign up today!

View details of SeQuent's funding rounds and investors

SeQuent's employee count trend

SeQuent has 2 employees as of Jul 26. Here is SeQuent's employee count trend over the years:

Uncover SeQuent's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SeQuent include Laurus Labs, Symbiotec and Embio. Here is the list of Top 10 competitors of SeQuent, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Laurus Labs 2005, Hyderabad (India), Public	Pharmaceutical and biotechnology company	$230M	F-Prime Capital, IKP Knowledge Park & 3 others	78/100
2nd	Symbiotec 2002, Indore (India), Acquired	Manufacturer of non sterile steroid hormone based APIs and intermediates	$61.1M	Franklin Templeton Investments, Actis & 21 others	64/100
3rd	Embio 1986, Mumbai (India), Late Stage	Contract research and manufacturing company engaged in APIs and chiral intermediates	$50.3M	UTI, GURU NARAYAN FINCAP & 26 others	58/100
4th	NGL Fine Chem 1981, Mumbai (India), Public	CDMO specializing in multi stage organic synthesis of generic APIs and fine chemicals	-	-	59/100
5th	Neuland 1984, Hyderabad (India), Public	Manufacturer of active pharmaceutical ingredients (APIs) and peptides	-	India Capital Growth, InvAscent & 1 others	58/100
6th	Snapdragon Chemistry 2014, Cambridge (United States), Acquired	CDMO providing API development, manufacturing, and analytical services	-	Asymchem, C2I Accelerator & 1 others	55/100
7th	SeQuent 2002, Bengaluru (India), Acquired	APIs Manufacturer	-	Nepean Capital, Thecarlylegroup.fr & 2 others	54/100
8th	ST PHARM 2008, Siheung si (South Korea), Public	CDMO providing oligonucleotide, mRNA, and small molecule services	-	E&Investment, Synergy IB investment & 1 others	54/100
9th	Hikal 1988, Mumbai (India), Public	Traditional company offering contract research, custom synthesis & custom manufacturing of APIs and intermediates	-	IFC	53/100
10th	Enaltec Labs 2006, Mumbai (India), Acquired	Provider of complex small-volume technology-driven pharmaceutical products	$8.56M	InvAscent, Medtech Global & 7 others	52/100